Goto, Tomoko
Shiraishi, Atsushi
Ohashi, Yuichi
Negishi, Kazuno
Tsubota, Kazuo
Nakamura, Yo
Hieda, Osamu
Sotozono, Chie
Kinoshita, Shigeru
Article History
Received: 3 November 2020
Accepted: 26 March 2021
First Online: 29 May 2021
Conflict of interest
: T. Goto, None; A. Shiraishi, None; Y. Ohashi, None; K. Negishi, Grant, Financial support (RE Medical, Bausch + Lomb, Wakamoto, TORAY, Universal View, Fuji Xerox), Grant, Honorarium for Lecturing, Financial support (HOYA, AMO, Kowa, Senju, Santen, Alcon), Grant, Honorarium for Lecturing (M3, Chuo Sangio, Otsuka, Qualitas, NIDEK), Tsubota Laboratory and the author are applicant for the patent of potential products for myopia suppression; K. Tsubota, Executive (Tsubota Laboratory); Y. Nakamura, None; O. Hieda, None; C. Sotozono, Lecture fee (Otsuka, Santen, Senju, TOA); S. Kinoshita, Honorarium for Lecturing, Consulting (Santen, Senju, Otsuka), Honorarium for Lecturing (Kowa), Senju and the author own the patent for the use of ROCK inhibitor. CorneaGen and the author own the patent for the use of ROCK inhibitor. Santen and the author own the patent for glaucoma-related genes. Sysmex and the author are applicants for the patent for SJS-related genes.